TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options Under Clinical Evaluation
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Osteosarcoma and UPS of Bone With Metastatic Disease at Diagnosis
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Source links and citations
The following are examples of national and/or institutional clinical trials that are currently being conducted:
AOST2031 (NCT05235165) (Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma): This phase III trial compares the effect of thoracotomy with thoracoscopic surgery (video-assisted thoracoscopic surgery) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). This trial is being done to evaluate the two different surgery methods for these patients and to determine which procedure is better.
Source links and citations
AOST2032 (NCT05691478) (A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma): This trial starts with a feasibility phase for patients with high-risk osteosarcoma who have a resectable primary tumor. The feasibility phase will be followed by a randomized study comparing chemotherapy using methotrexate, doxorubicin, and cisplatin (MAP) with MAP and cabozantinib for patients with newly diagnosed localized and metastatic osteosarcoma.
Source links and citations
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Preserved source evidence · Not medical advice